Bafna Pharmaceuticals Ltd.

91.50 +0.53 ▲0.6%

26 February 2024, 01:45:00 PM
Volume: 1,920

Company Profile

Sector Healthcare Sector Icon Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Industry Icon Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.bafnapharma.com
Market Cap 217.64 Cr.
Enterprise Value(EV) 231.79 Cr. 2023-09
Financial Indicators
Earnings per share (EPS) 4.76 Trailing Twelve Months Ending 2023-12
Price-Earning Ratio (PE) 19.33 Trailing Twelve Months Ending 2023-12
Industry PE 41.88 Trailing Twelve Months Ending 2023-12
Book Value / Share 33.57 Trailing Twelve Months Ending 2023-12
Price to Book Value 2.74 Calculated using Price: 92.00
Dividend Yield 0.00 Period Ending 2023-03
No. of Shares Subscribed 2.37 Cr. 23,656,335 Shares
FaceValue 10
About Bafna Pharmaceuticals Ltd.
Bafna Pharmaceuticals was incepted by Bafna Mahaveer Chand in 1981 as a proprietary concern. It was converted into a public limited company on 28th march 1995. The company started its own manufacturing unit in October 1984.

Bafna Pharmaceuticals Ltd. Delivery

Delivered Qty
Traded Qty

Bafna Pharmaceuticals Ltd. Performance

1 Day
+0.58%
1 Week
+1.64%
1 Month
-5.67%
3 Month
+6.21%
6 Month
-16.88%
1 Year
-3.68%
2 Year
-31.74%
5 Year
+852.13%
10 Year
+321.66%

Bafna Pharmaceuticals Ltd. Fundamental Ratios

9 years 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03 2023-03
Return on Equity (%) 9.22 -18.69 -37.05 -40.37 -64.36 -22.93 22.26 8.79 16.75
Return on Capital Employed (%) 12.56 -0.04 -5.98 -6.97 -20.9 -2.95 10.62 8.42 16.12
Return on Assets (%) 2.99 -6.58 -10.49 -11.17 -15.9 -1.96 7.4 5.91 10.32

Bafna Pharmaceuticals Ltd. Balance Sheet

Particulars 10 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-09* Rs. Cr.
Shh. Funds 72 59 45 41 21 51 57 62 73 82
Non Curr. Liab. 14 39 42 28 29 3 5 6 10 8
Curr. Liab. 100 87 81 59 71 17 24 22 46 44
Minority Int.
Equity & Liab. 185 185 167 128 121 71 86 90 130 135
Non Curr. Assets 68 65 90 79 72 35 37 39 42 44
Curr. Assets 117 119 77 48 48 36 50 51 87 91
Misc. Exp. not W/O 1
Total Assets 185 185 167 128 121 71 86 90 130 135

Bafna Pharmaceuticals Ltd. Profit and Loss

Particulars 10 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-12 Rs. Cr. TTM
Net Sales 143 85 65 47 44 42 71 85 115 153
Other Income 1 1 1 31 0 0 1 2 3 3
Total Income 144 87 66 78 44 43 72 87 119 157
Total Expenditure -117 -83 -70 -82 -57 -41 -61 -73 -100 -137
PBIDT 26 4 -4 -4 -13 1 11 14 19 19
Interest -12 -12 -11 -7 -2 0 -1 -1 -2 -2
Depreciation -5 -4 -4 -4 -3 -3 -4 -5 -5 -5
Taxation 0 0 1 -2 -2 0 0
Exceptional Items -3 -2
PAT 6 -12 -18 -16 -20 -2 6 5 11 11
Adjusted EPS 3 -7 -10 -7 -8 -8 2 2 5 5

Bafna Pharmaceuticals Ltd. Cash Flow

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Cash Fr. Operatn. 1 9 -3 20 -7 -1 -34 -14 10 5
Cash Fr. Inv. -5 56 -1 -14 38 4 33 -5 -7 -7
Cash Fr. Finan. -14 -66 4 -5 -31 -2 7 12 -5 10
Net Change -18 0 0 0 0 6 -7 -2 8
Cash & Cash Eqvt 2 2 3 3 3 3 8 2 0 8

Bafna Pharmaceuticals Ltd. Shareholding Pattern

9 Qtrs 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%) 2023-03 (%) 2023-06 (%) 2023-09 (%) 2023-12 (%)
Promoter 90.42 90.42 90.12 90.00 90.02 90.00 90.00 88.74 88.43
Public 9.58 9.58 9.88 10.00 9.98 10.00 10.00 11.26 11.57
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Bafna Pharmaceuticals Ltd. Announcements

Wed, 14 Feb 2024
Announcement under Regulation 30 (LODR)-Newspaper Publication
we have furnished herewith newspaper clippings of Un-audited Standalone Financial Results of the Company for the quarter and nine months ended December 31 2023 which was approved by the Board in its meeting held on February 12 2024 and published in the newspapers namely in Makkal Kural (Tamil edition) and Business Standard (English edition) on Tuesday February 13 2024.
Mon, 12 Feb 2024
Un-Audited Standalone Financial Results For The Quarter Ended December 31 2023.
we wish to inform that at the meeting of the Board of Directors of the Company held today i.e. February 12 2024 Monday the results of the quarter ended on December 31 2023 duly reviewed by Audit Committee inter-alia has been considered and approved by the Board of Directors of the Company.
Fri, 02 Feb 2024
Board Meeting Intimation for Intimation Of Meeting Of Board Of Directors - Approval Of Q3 FY24 Financial Results.
BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2024 inter alia to consider and approve A meeting of board of directors of the Company is scheduled to be held on Monday February 12 2024 inter-alia to consider and approve the Un-Audited Standalone Financial Results of the Company for the third quarter of FY24 ended December 31 2023 together with the Limited Review Report for the said period.

Bafna Pharmaceuticals Ltd. Technical Scans

Fri, 23 Feb 2024
Higher Delivery Quantity Higher Delivery Quantity
Higher Trade Quantity Higher Trade Quantity
Higher Trade and Delivery Quantity Higher Trade and Delivery Quantity
Opening at Low Opening at Low
Close Below Last Month Low Close Below Last Month Low

Bafna Pharmaceuticals Ltd. Related Stocks

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 374,572.18 1,553.65 -0.5%
Cipla Ltd. 118,375.92 1,469.85 +0.2%
Dr. Reddy's Laboratories Ltd. 107,511.08 6,427.90 -0.2%
Apollo Hospitals Enterprise Ltd. 97,345.81 6,615.05 -2.4%
Divi's Laboratories Ltd. 96,748.70 3,565.50 -2.3%
Zydus Lifesciences Ltd. 93,335.34 939.95 +1.8%
Torrent Pharmaceuticals Ltd. 88,913.00 2,625.25 -0.1%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 42.06 1,553.65 -0.5%
Cipla Ltd. Consolidated 2023-12 31.92 1,469.85 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 20.56 6,427.90 -0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 123.33 6,615.05 -2.4%
Divi's Laboratories Ltd. Consolidated 2023-12 69.96 3,565.50 -2.3%
Zydus Lifesciences Ltd. Consolidated 2023-12 31.39 939.95 +1.8%
Torrent Pharmaceuticals Ltd. Consolidated 2023-12 59.51 2,625.25 -0.1%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 6.00 1,553.65 -0.5%
Cipla Ltd. Consolidated 2023-12 4.57 1,469.85 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 4.00 6,427.90 -0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 14.41 6,615.05 -2.4%
Divi's Laboratories Ltd. Consolidated 2023-12 7.42 3,565.50 -2.3%
Zydus Lifesciences Ltd. Consolidated 2023-12 4.80 939.95 +1.8%
Torrent Pharmaceuticals Ltd. Consolidated 2023-12 12.43 2,625.25 -0.1%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 0.11 1,553.65 -0.5%
Cipla Ltd. Consolidated 2023-03 0.02 1,469.85 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 0.06 6,427.90 -0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 0.44 6,615.05 -2.4%
Divi's Laboratories Ltd. Consolidated 2023-03 0.00 3,565.50 -2.3%
Zydus Lifesciences Ltd. Consolidated 2023-03 0.07 939.95 +1.8%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 0.85 2,625.25 -0.1%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,553.65 -0.5%
Cipla Ltd. Consolidated 2023-03 12.85 1,469.85 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,427.90 -0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,615.05 -2.4%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,565.50 -2.3%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 939.95 +1.8%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 20.50 2,625.25 -0.1%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,553.65 -0.5%
Cipla Ltd. Consolidated 2023-03 12.85 1,469.85 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,427.90 -0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,615.05 -2.4%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,565.50 -2.3%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 939.95 +1.8%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 20.50 2,625.25 -0.1%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 43,885.68 1,553.65 -0.5%
Cipla Ltd. Consolidated 2023-03 22,753.12 1,469.85 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 24,669.70 6,427.90 -0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 16,612.50 6,615.05 -2.4%
Divi's Laboratories Ltd. Consolidated 2023-03 7,767.51 3,565.50 -2.3%
Zydus Lifesciences Ltd. Consolidated 2023-03 17,237.40 939.95 +1.8%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 9,620.15 2,625.25 -0.1%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 8,560.84 1,553.65 -0.5%
Cipla Ltd. Consolidated 2023-03 2,835.49 1,469.85 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 4,507.30 6,427.90 -0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 887.50 6,615.05 -2.4%
Divi's Laboratories Ltd. Consolidated 2023-03 1,823.38 3,565.50 -2.3%
Zydus Lifesciences Ltd. Consolidated 2023-03 2,001.90 939.95 +1.8%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 1,245.23 2,625.25 -0.1%

Bafna Pharmaceuticals Ltd. FAQ's

What is Bafna Pharma share price?

Can I buy Bafna Pharma shares now?

What is the Market Cap of Bafna Pharma?

What are the key metrics to analyse Bafna Pharma?

What is the 52 Week High and Low of Bafna Pharma?

What is the trend of Bafna Pharma share price?